Compare ESPR & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | UDMY |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 716.5M |
| IPO Year | 2013 | 2021 |
| Metric | ESPR | UDMY |
|---|---|---|
| Price | $1.90 | $4.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $8.75 | ★ $9.29 |
| AVG Volume (30 Days) | ★ 7.4M | 1.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.71 | ★ 105.36 |
| EPS | N/A | ★ 0.03 |
| Revenue | $403,135,000.00 | ★ $789,844,000.00 |
| Revenue This Year | N/A | $4.12 |
| Revenue Next Year | $12.81 | $4.54 |
| P/E Ratio | ★ N/A | $157.83 |
| Revenue Growth | ★ 21.31 | 0.42 |
| 52 Week Low | $0.73 | $4.18 |
| 52 Week High | $4.18 | $8.09 |
| Indicator | ESPR | UDMY |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 36.92 |
| Support Level | $1.34 | N/A |
| Resistance Level | $2.08 | $5.18 |
| Average True Range (ATR) | 0.16 | 0.29 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 11.89 | 12.55 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.